Rapidly progressive glomerulonephritis laboratory findings

Rapidly progressive glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Rapidly progressive glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray Findings
CT-scan Findings
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Rapidly progressive glomerulonephritis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Rapidly progressive glomerulonephritis laboratory findings
CDC on Rapidly progressive glomerulonephritis laboratory findings
Rapidly progressive glomerulonephritis laboratory findings in the news
Blogs on Rapidly progressive glomerulonephritis laboratory findings
Directions to Hospitals Treating Rapidly progressive glomerulonephritis
Risk calculators and risk factors for Rapidly progressive glomerulonephritis laboratory findings

{{CMG{{

Laboratory Findings

Serum analysis often aids in the diagnosis of a specific underlying disease. The presence of anti-GBM antibodies suggests type I RPGN; antinuclear antibodies (ANA) may support a diagnosis of systemic lupus erythematosus and type II RPGN; and type III and idiopathic RPGN are frequently associated with ANCA-positive serum.